ArticleFrontiers in immunology2024

Quantification of PD-L1 expression and tumor mutational burden in biologically distinct advanced pancreatic cancers responding to pembrolizumab: case reports.

Kevin Y Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.